Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T16:00:41.811Z.
Calculation as of: 2026-10-06T16:00:41.811Z.
Quote observation: 2026-10-06T16:00:10.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 8d554412806125b06490580232e6d80b3120c6a72214b764814008bb1d876b03
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Ainos, Inc.
Market Cap
$9.79M
EV/EBITDA Ratio
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO |
|---|---|---|
| Ainos, Inc. (AIMD) | $9.79M | N/A |
| MetaVia Inc. (MTVA)vs › | $9.71M | N/A |
| NeuroOne Medical Technologies Corporation (NMTC)vs › | $10.01M | N/A |
| Medicus Pharma Ltd. Common Stock (MDCX)vs › | $10.06M | N/A |
| Jasper Therapeutics, Inc. (JSPR)vs › | $9.34M | N/A |
| Advanced Biomed Inc. Common Stock (ADVB)vs › | $9.22M | N/A |
| Satellos Bioscience Inc. (MSLE)vs › | $10.43M | N/A |
| SeaStar Medical Holding Corporation (ICU)vs › | $9.10M | N/A |
| CytoMed Therapeutics Limited (GDTC)vs › | $10.52M | N/A |
| Polyrizon Ltd. (PLRZ)vs › | $10.53M | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
